Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
At LSPN Fall North America, in-house counsel offered guidance on how to nail the perfect patent application. Marisa Woutersen reports.   17 October 2024
Careers
Former patent examiner and federal clerk brings expertise in cutting-edge technologies to the US firm.   17 October 2024
Americas
As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.   17 October 2024
Americas
UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.   16 October 2024
Asia
The Beijing IP court’s decision to revive a key semaglutide patent based on experimental data has far-reaching legal and economic implications, says Jennifer Che of Eagle IP   15 October 2024
Americas
Danish pharma company asserts 10 patents for drug that improves blood sugar levels in Type 2 diabetes patients | Like Novo’s Ozempic, the disputed drug can be used off-label to achieve weight loss.   15 October 2024
Europe
Global law firm recruits former CMS partner to IP practice I Patent lawyer brings expertise in pharmaceuticals, tech and AI   15 October 2024
Careers
US firm doubles down in Europe with another big name recruit | Tech and life sciences litigation at the UPC a target | Powell will 'always be a friend of the firm’ says ex-colleague Penny Gilbert | Move ends speculation about Powell’s future after August resignation.   14 October 2024
Europe
Value-for-money UPC is worth it says GSK corporate counsel | Court offers alternative to costly US litigation | Head of vaccine patents says UPC offers “strategic plank” in Europe.   10 October 2024
Europe
Duo successfully invalidate two CureVac patents in the UK | High Court deems patents invalid due to lack of inventive step and insufficient technical contribution | CureVac “disappointed” but stressed outcome does not affect ongoing litigation in Germany and US.   10 October 2024